Abstract
Summary. Acute and chronic L-carnitine application exerts protective effects in a number of cardiac diseases. These favourable effects are attributed to improvements of the energy metabolism and have been found both in animal experiments and in man. In order to investigate the effect of long-time oral L-carnitine substitution on physical performance, 41 patients suffering from class NYHA II or III cardiac insufficiency were recruited for a clinical study. Following the double-blind, randomized, placebo-controlled design of the study, 20 patients were given 3 × 1g L-carnitine daily for 120 days whereas the control group (21 patients) received placebo. Bicycle ergometer tests were used to determine maximum performance, systolic and diastolic blood pressure, heart rate, and ST changes. Four series of tests were carried out: on day 0 (before the first substrate application), on the 60th and the 120th day (during L-carnitine or placebo application), and on the 180th day (60 days after the end of substitution). A significant improvement in performance (significantly higher maximum performance during bicycle ergometry) could be found within the carnitine group on the 60th and 120th day of L-carnitine application; and haemodynamical parameters showed a tendency to improve, too. These effects, which were attributed to L-carnitine, could be detected even 60 days after the end of substitution. No corresponding changes were found in the placebo group.
The findings presented in this paper support suggestions of other authors that L-carnitine in combination with the usual medication (digitalis, β-blockers, calcium antagonists, nitrates) improves performance and effort tolerance in patients with cardiac insufficiency. Moreover, the findings suggest a favourable long-term effect, which lasts beyond the actual L-carnitine application, on the performance of patients with advanced cardiac insufficiency.
Similar content being viewed by others
References
Bremer J. Carnitine—Metabolism and functions. Phys Revs 1983;63:1420–1480.
Bieber LL. Carnitine. Ann Rev Biochem 1988;57:261–283.
Ramsay RR, Tubbs PK. The mechanism of fatty acid uptake by heart mitochondria: An acylcarnitine-carnitine exchange. FEBS Lett 1975;54:21–25.
Bremer J, Hokland B. Role of carnitine-dependent metabolic pathways in heart disease without primary ischemia. Z Kardiol 1987;76(Suppl 5):9–13.
Liedtke AJ. Alteration of carbohydrate and lipid metabolism in the acutely ischemic heart. Prog Cardiovasc Dis 1981;25:321–330.
Opie LH. Carbohydrates and Lipids. In: L Opie, The Heart: Physiology, Metabolism, Pharmacology and Therapy. London: Grune & Stratton Inc., 1986: 118–135.
Feuvray D, Leblond Y. Metabolism of long chain fatty acids in the normal and in the pathological heart: Effects of ischemia. Diabetes Metab 1984;10:316–323.
Schoonderwoerd R, Broekhoven-Schokker S, Hülsmann WC, Stam HCG. Enhanced lipolysis of mycardial triglyceroles during low-flow ischemia and anoxia in the isolated rat heart. Bas Res Cardiol 1989;84:165–173.
Van der Vusse GJ, Glatz JFC, Stam HCG, Reneman RS. Fatty acid homeostasis in the normoxic and ischemic heart. Phys Rev 1992;72:881–940.
Shug AL, Subramanian R. Modulation of adenine nucleotide translocase activity during myocardial ischemia. Z Kardiol 1987;76(Suppl 5):26–33
Bieber LL, Emaus R, Valkner K, Farrell S. Possible functions of short-chain and medium-chain carnitine acyltransferases. Fed Proc 1982;41:2858–2862.
Spagnoli LG, Corsi M, Villaschi S, Palmieri G, Maccari F. Myocardial carnitine deficiency in acute myocardial infarction. Lancet 1982;1:1419–1420.
Suzuki Y, Masumura Y, Kobayashi A, Yamazaki N, Harada Y, Osawa M. Myocardial carnitine deficiency in chronic heart failure. Lancet 1982;1:116
Paulson DJ, Shug AL. Tissue specific depletion of L-carnitine in rat heart and skeletal muscle by D-carnitine. Life Sci 1981;28:2931–2938.
Löster H, Punzel M. Effects of L-carnitine on mechanical recovery of isolated rat hearts in relation to the perfusion with glucose and palmitate. Mol Cell Biochem 1998;185:65–75.
Broderick TL, Quinney HA, Lopaschuk GD. Carnitine stimulation of glucose oxidation in fatty acid perfused isolated working rat heart. J Biol Chem 1992;267:3758–3763.
Engel AG, Angelini C. Carnitine deficiency of human muscle with associated lipid storage myopathy: A new syndrome. Science 1973;179:899–902.
Borchard U. L-Carnitin—ein neuer therapeutischer Ansatz bei Kardiomyopathie und ischämischen Herzerkrankungen. Z prakt Kardioangiologie 1987;(Sonderheft II):3–5.
Opie LH. Role of carnitine in fatty acid metabolism of normal and ischemic myocardium. Am Heart J 1979;97:375–388.
Bartels GL, Remme WJ, Pillay M, et al. Acute improvement of cardiac function with intravenous L-propionylcarnitine in humans. J Cardiovasc Pharmacol 1992;20:157–164.
Kamikawa T, Suzuki Y, Kobayashi A, et al. Effects of L-carnitine on exercise tolerance in patients with stable angina pectoris. Jpn Heart J 1984;25:587–597.
Lagioia R, Scutinio D, Mangini SG, et al. Propionyl-L-carnitine: A new compound in the metabolic approach to the treatment of effort angina. Int J Cardiol 1992;34:167–172.
Liedtke AJ, De Maison L, Nellis SH. Effects of L-propionylcarnitine on mechanical recovery during reflow in intact hearts. Am J Physiol 1988;255:H169–H176.
Schiavoni G, Pennestri F, Mongiardo R, Mazzari M, Manzoli U. Cardiodynamic effects of L-carnitine in ischemic cardiopathy. Drugs Exptl Clin Res 1983;11:171–185.
Yang XP, Samaja M, English E, et al. Hemodynamic and metabolic activities of propionyl-L-carnitine in rats with pressure-overload cardiac hypertrophy. J Cardiovasc Pharmacol 1992;20:88–98.
Cacciatore L, Cerio R, Ciarimboli M, et al. The therapeuthic effect of L-carnitine in patients with exercise-induced stable angina: a controlled study. Drugs Exptl Clin Res 1991;17:225–235.
Cherchi A, Lai C, Angelino F, et al. Effects of L-carnitine on exercise tolerance in chronic stable angina: A multicenter, double-blind, randomized, placebo-controlled crossover study. Int J Clin Pharmacol Ther Toxicol 1985;23:569–572.
Canale C, Terrachini V, Biagini A, et al. Bicycle ergometer and echocardiographic study in healthy subjects and patients with angina pectoris after administration of L-carnitine: Semiautomatic computerized analysis of M-mode tracings. Int J Clin Pharmacol Ther Toxicol 1988;26:221–224.
Cherchi A, Lai C, Onnis E, et al. Propionyl carnitine in stable effort angina. Cardiovasc Drugs Ther 1990;4:481–486.
Gasparetto A, Corbucci GG, De Blasi AA, et al. Influence of acetyl-L-carnitine infusion on haemodynamic parameters and survival of circulatory-shock patients. Int J Clin Pharmacol Res 1991;11:83–92.
Ghidini O, Azzurro M, Vita G, Sartori G. Evaluation of the therapeutic efficacy of L-carnitine in congestive heart failure. Int J Clin Pharmacol Ther Toxicol 1988;26:217–220.
Giordano MP, Corsi M, Roncarolo P et al. Effect of L-carnitine on systolic time intervals in coronary artery disease. Curr Ther Res 1983;33:305–311.
Fazekas T, Csati S, Selmeczi A, Udvary E, Szekeres L. Effects of L-carnitine in acute myocardial ischemia. Acta Physiol Hung 1986;67:199–205.
Biagini A, Opie LH, Rovai D, Mazzei MG, Carpeggiani C, Maseri A. Intravenous dl-carnitine fails to increase the double-product during atrial pacing in patients with effort angina. A double-blind randomized study. G Ital Cardiol 1983;13:291–294.
Bartels GL, Remme WJ, Pillay M, Schönfeld DHW, Kruijssen, DACM. Effects of L-propionylcarnitine on ischemia induced myocardial dysfunction in men with angina pectoris. Am J Cardiol 1994;74:125–130.
Ferrari R, Di Lisa F, De Jong JW, et al. Prolonged propionyl-L-carnitine pre-treatment of rabbit: biochemical, hemodynamic and electrophysiological effects on myocardium. J Mol Cell Cardiol 1992;24:219–232.
Ferrari F, Cucchini F, Visioli O. The metabolic effects of L-carnitine in angina pectoris. Int J Cardiol 1984;5:213–216.
Ferrari R, Visioli O. Effects of L-carnitine in coronary artery disease patients. In: Ferrari R, DiMauro S, Sherwood G, eds. L-Carnitine and Its Role in Medicine: From Function to Therapy. New York: Academic Press, 1992:265–282.
Brevetti G, Perna S. Metabolic and clinical effects of L-carnitine in peripheral vascular disease. In: Ferrari R, Di-Mauro S, Sherwood G, eds. L-Carnitine and Its Role in Medicine: From Function to Therapy. New York: Academic Press, 1992:359–378
Cherchi A, Fonzo R, Lai C, Mercuro G, Corsi M. Influence of carnitine on the effort tolerance test in angina pectoris. Boll Soc Ital Cardiol 1978;23:71–89.
Thomsen JH, Shug AL, Yap VU, Patel AK, Karras TJ, DeFelice SL. Improved pacing tolerance of the ischemic human myocardium after administration of carnitine. Am J Cardiol 1979;43:300–305.
Kosolcharoen P, Nappi J, Peduzzi P, et al. Improved exercise tolerance after administration of carnitine. Curr Ther Res 1981;30:753–764.
Hülsmann WC, Dubelaar N. Carnitine in metabolism of paced cardiac and skeletal muscles: prevention of acidosis and improvement of vascular flow. In: Ferrari R, DiMauro S, Sherwood G, eds. L-Carnitine and Its Role in Medicine: From Function to Therapy. New York: Academic Press, 1992:345–358
Regitz V, Fleck E. Role of carnitine in heart failure. In: Ferrari R, DiMauro S, Sherwood G, eds. L-Carnitine and Its Role in Medicine: From Function to Therapy. New York: Academic Press, 1992:295–323
Kobayashi A, Fujisawa S. Effect of L-carnitine on mitochondrial acyl CoA esters in the ischemic dog heart. J Mol Cell Cardiol 1994;26:499–508.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Löster, H., Miehe, K., Punzel, M. et al. Prolonged Oral L-carnitine Substitution Increases Bicycle Ergometer Performance in Patients with Severe, Ischemically Induced Cardiac Insufficiency. Cardiovasc Drugs Ther 13, 537–546 (1999). https://doi.org/10.1023/A:1007883822625
Issue Date:
DOI: https://doi.org/10.1023/A:1007883822625